Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine

Gynecologic Oncology

Volumn 141, Issue 1, 2016, Pages 86-94

  Zamarin, Dmitriy ^a   Jazaeri, Amir A ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Cervical cancer; Checkpoint inhibitors; Endometrial cancer; Gynecologic cancers; Immuno oncology; Immunotherapy; Ovarian cancer

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; CA 125 ANTIGEN; CANCER VACCINE; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPITHELIAL CELL ADHESION MOLECULE; FOLATE RECEPTOR 1; INTERFERON; IPILIMUMAB; MOTOLIMOD; NIVOLUMAB; ONCOLYTIC VIRUS; PEMBROLIZUMAB; PEPTIDE VACCINE; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR AGONIST; TUMOR ANTIGEN; VACCINIA VACCINE; PDCD1 PROTEIN, HUMAN;

ARTICLE; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CELL THERAPY; ENDOMETRIUM CANCER; FEMALE GENITAL TRACT CANCER; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; LISTERIA MONOCYTOGENES; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER; VACCINIA; WART VIRUS; ADOPTIVE IMMUNOTHERAPY; ANTAGONISTS AND INHIBITORS; FEMALE; GENITAL NEOPLASMS, FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; PHYSIOLOGY;

CANCER VACCINES; CTLA-4 ANTIGEN; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; ONCOLYTIC VIROTHERAPY; PRECISION MEDICINE; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES;

EID: 84961848658     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.12.030     Document Type: Article

References (174)

1. C.M. Koebel, W. Vermi, J.B. Swann, N. Zerafa, S.J. Rodig, L.J. Old, and et al. Adaptive immunity maintains occult cancer in an equilibrium state Nature 450 2007 903 907
2. G. Willimsky, and T. Blankenstein Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance Nature 437 2005 141 146
3. H. Kono, and K.L. Rock How dying cells alert the immune system to danger Nat. Rev. Immunol. 8 2008 279 289
4. L. Chen, and D.B. Flies Molecular mechanisms of T cell co-stimulation and co-inhibition Nat. Rev. Immunol. 13 2013 227 242
5. H. Harlin, Y. Meng, A.C. Peterson, Y. Zha, M. Tretiakova, C. Slingluff, and et al. Chemokine expression in melanoma metastases associated with CD8 + T-cell recruitment Cancer Res. 69 2009 3077 3085
6. K. Franciszkiewicz, A. Boissonnas, M. Boutet, C. Combadiere, and F. Mami-Chouaib Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response Cancer Res. 72 2012 6325 6332
7. L. Zitvogel, A. Tesniere, and G. Kroemer Cancer despite immunosurveillance: immunoselection and immunosubversion Nat. Rev. Immunol. 6 2006 715 727
8. G.T. Motz, and G. Coukos Deciphering and reversing tumor immune suppression Immunity 39 2013 61 73
9. L. Zhang, J.R. Conejo-Garcia, D. Katsaros, P.A. Gimotty, M. Massobrio, G. Regnani, and et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer N. Engl. J. Med. 348 2003 203 213
10. E. Sato, S.H. Olson, J. Ahn, B. Bundy, H. Nishikawa, F. Qian, and et al. Intraepithelial CD8 + tumor-infiltrating lymphocytes and a high CD8 +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer Proc. Natl. Acad. Sci. U. S. A. 102 2005 18538 18543
11. K. Schlienger, C.S. Chu, E.Y. Woo, P.M. Rivers, A.J. Toll, B. Hudson, and et al. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients Clin. Cancer Res. 9 2003 1517 1527
12. V. Goodell, L.G. Salazar, N. Urban, C.W. Drescher, H. Gray, R.E. Swensen, and et al. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer J. Clin. Oncol. 24 2006 762 768
13. K. Hayashi, K. Yonamine, K. Masuko-Hongo, T. Iida, K. Yamamoto, K. Nishioka, and et al. Clonal expansion of T cells that are specific for autologous ovarian tumor among tumor-infiltrating T cells in humans Gynecol. Oncol. 74 1999 86 92
14. E. Halapi, Y. Yamamoto, C. Juhlin, M. Jeddi-Tehrani, J. Grunewald, R. Andersson, and et al. Restricted T cell receptor V-beta and J-beta usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas Cancer Immunol. Immunother. 36 1993 191 197
15. B. Fisk, T.L. Blevins, J.T. Wharton, and C.G. Ioannides Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines J. Exp. Med. 181 1995 2109 2117
16. S. Kooi, R.S. Freedman, J. Rodriguez-Villanueva, and C.D. Platsoucas Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells Lymphokine Cytokine Res. 12 1993 429 437
17. G.E. Peoples, D.D. Schoof, J.V. Andrews, P.S. Goedegebuure, and T.J. Eberlein T-cell recognition of ovarian cancer Surgery 114 1993 227 234
18. R.D. Dadmarz, A. Ordoubadi, A. Mixon, C.O. Thompson, K.C. Barracchini, Y.M. Hijazi, and et al. Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion Cancer J. Sci. Am. 2 1996 263 272
19. A.D. Santin, S. Bellone, A. Ravaggi, S. Pecorelli, M.J. Cannon, and G.P. Parham Induction of ovarian tumor-specific CD8 + cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells Obstet. Gynecol. 96 2000 422 430
20. G.E. Peoples, P.S. Goedegebuure, R. Smith, D.C. Linehan, I. Yoshino, and T.J. Eberlein Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide Proc. Natl. Acad. Sci. U. S. A. 92 1995 432 436
21. F. Bellati, C. Napoletano, M.L. Gasparri, V. Visconti, I.G. Zizzari, I. Ruscito, and et al. Monoclonal antibodies in gynecological cancer: a critical point of view Clin. Dev. Immunol. 2011 2011 890758
22. J.M. Reichert, and E. Dhimolea The future of antibodies as cancer drugs Drug Discov. Today 2012
23. N. Leffers, T. Daemen, W. Helfrich, H.M. Boezen, B.J. Cohlen, C.J. Melief, and et al. Antigen-specific active immunotherapy for ovarian cancer Cochrane Database Syst. Rev. 9 2014 CD007287
24. R.C. Bast Jr., M. Feeney, H. Lazarus, L.M. Nadler, R.B. Colvin, and R.C. Knapp Reactivity of a monoclonal antibody with human ovarian carcinoma J. Clin. Invest. 68 1981 1331 1337
25. B.W. Yin, A. Dnistrian, and K.O. Lloyd Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene Int. J. Cancer 98 2002 737 740
26. T.J. O'Brien, J.B. Beard, L.J. Underwood, R.A. Dennis, A.D. Santin, and L. York The CA 125 gene: an extracellular superstructure dominated by repeat sequences Tumour Biol. 22 2001 348 366
27. A.N. Gordon, B.C. Schultes, H. Gallion, R. Edwards, T.L. Whiteside, J.M. Cermak, and et al. CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients Gynecol. Oncol. 94 2004 340 351
28. V.J. Mobus, R.P. Baum, M. Bolle, R. Kreienberg, A.A. Noujaim, B.C. Schultes, and et al. Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer Am. J. Obstet. Gynecol. 189 2003 28 36
29. A.A. Noujaim, B.C. Schultes, R.P. Baum, and R. Madiyalakan Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13 - evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo Cancer Biother. Radiopharm. 16 2001 187 203
30. J. Berek, P. Taylor, W. McGuire, L.M. Smith, B. Schultes, and C.F. Nicodemus Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer J. Clin. Oncol. 27 2009 418 425
31. G. Spizzo, P. Went, S. Dirnhofer, P. Obrist, H. Moch, P.A. Baeuerle, and et al. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer Gynecol. Oncol. 103 2006 483 488
32. M.M. Heiss, P. Murawa, P. Koralewski, E. Kutarska, O.O. Kolesnik, V.V. Ivanchenko, and et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial Int. J. Cancer 127 2010 2209 2221
33. B. Schlereth, I. Fichtner, G. Lorenczewski, P. Kleindienst, K. Brischwein, A. da Silva, and et al. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM -/CD3-bispecific antibody construct Cancer Res. 65 2005 2882 2889
34. F. Ferrari, S. Bellone, J. Black, C.L. Schwab, S. Lopez, E. Cocco, and et al. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE(R)), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro J. Exp. Clin. Cancer Res. 34 2015 123
35. D.P. English, S. Bellone, C.L. Schwab, D.M. Roque, S. Lopez, I. Bortolomai, and et al. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo Cancer 121 2015 403 412
36. J.F. Ross, P.K. Chaudhuri, and M. Ratnam Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications Cancer 73 1994 2432 2443
37. J.A. Konner, K.M. Bell-McGuinn, P. Sabbatini, M.L. Hensley, W.P. Tew, N. Pandit-Taskar, and et al. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study Clin. Cancer Res. 16 2010 5288 5295
38. D.K. Armstrong, A.J. White, S.C. Weil, M. Phillips, and R.L. Coleman Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer Gynecol. Oncol. 129 2013 452 458
39. H. Borghaei, D.M. O'Malley, S.M. Seward, T.M. Bauer, R.P. Perez, A.M. Oza, and et al. Phase 1 study of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors J. Clin. Oncol. 33 2015 (Suppl.; abstr 5558)
40. N. Leffers, T. Daemen, W. Helfrich, H.M. Boezen, B.J. Cohlen, C.J. Melief, and H.W. Nijman Antigen-specific active immunotherapy for ovarian cancer Cochrane Database Syst. Rev. 17 9 2014 10.1002/14651858.CD007287.pub3 PMID: 25229990
41. C.S. Chu, S.H. Kim, C.H. June, and G. Coukos Immunotherapy opportunities in ovarian cancer Expert. Rev. Anticancer. Ther. 8 2008 243 257
42. K. Odunsi, and P. Sabbatini Harnessing the immune system for ovarian cancer therapy Am. J. Reprod. Immunol. 59 2008 62 74
43. P. Sabbatini, and K. Odunsi Immunologic approaches to ovarian cancer treatment J. Clin. Oncol. 25 2007 2884 2893
44. C.F. Hung, T.C. Wu, A. Monie, and R. Roden Antigen-specific immunotherapy of cervical and ovarian cancer Immunol. Rev. 222 2008 43 69
45. P. Sabbatini, T. Tsuji, L. Ferran, E. Ritter, C. Sedrak, K. Tuballes, and et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients Clin. Cancer Res. 18 2012 6497 6508
46. P.J. Sabbatini, G. Ragupathi, C. Hood, C.A. Aghajanian, M. Juretzka, A. Iasonos, and et al. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer Clin. Cancer Res. 13 2007 4170 4177
47. N. Leffers, A.J. Lambeck, M.J. Gooden, B.N. Hoogeboom, R. Wolf, I.E. Hamming, and et al. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial Int. J. Cancer 125 2009 2104 2113
48. K.A. Chianese-Bullock, W.P. Irvin Jr., G.R. Petroni, C. Murphy, M. Smolkin, W.C. Olson, and et al. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer J. Immunother. 31 2008 420 430
49. S. Reinartz, S. Kohler, H. Schlebusch, K. Krista, P. Giffels, K. Renke, and et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II) Clin. Cancer Res. 10 2004 1580 1587
50. M. Wilson, J.A. Villella, N.L. Berinstein, J. Brown, S. Lheureux, A. Haley, and et al. Phase I/Ib clinical and immunologic assessment of immunotherapeutic vaccine, DPX-Survivac in women with ovarian, Fallopian tube, or peritoneal cancer (OC) J. Clin. Oncol. 32 5s 2014 (Suppl.; abstr 5555)
51. K. Odunsi, J. Matsuzaki, J. Karbach, A. Neumann, P. Mhawech-Fauceglia, A. Miller, and et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients Proc. Natl. Acad. Sci. U. S. A. 109 2012 5797 5802
52. M. Mohebtash, K.Y. Tsang, R.A. Madan, N.Y. Huen, D.J. Poole, C. Jochems, and et al. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer Clin. Cancer Res. 17 2011 7164 7173
53. H.J. Gray, and S.E. Gargosky Progression-free survival in ovarian cancer patients in second remission with mucin-1 autologous dendritic cell therapy J. Clin. Oncol. 32 5s 2014 (Suppl.; abstr 5504)
54. P. Sabbatini, J. Berek, A. Casado, K. Cwiertka, T. Pinter, A. Pluzanska, and et al. Abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response post first line chemotherapy: preliminary results of the randomized double blind, placebo controlled multi-center MIMOSA trial J. Clin. Oncol. 28 2010
55. J.B. Liao, and M.L. Disis Therapeutic vaccines for ovarian cancer Gynecol. Oncol. 130 2013 667 673
56. A. van Elsas, A.A. Hurwitz, and J.P. Allison Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation J. Exp. Med. 190 1999 355 366
57. A.A. Hurwitz, T.F. Yu, D.R. Leach, and J.P. Allison CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma Proc. Natl. Acad. Sci. U. S. A. 95 1998 10067 10071
58. M.A. Curran, and J.P. Allison Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors Cancer Res. 69 2009 7747 7755
59. R.A. Wilcox, D.B. Flies, G. Zhu, A.J. Johnson, K. Tamada, A.I. Chapoval, and et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors J. Clin. Investig. 109 2002 651 659
60. D. Ito, K. Ogasawara, K. Iwabuchi, Y. Inuyama, and K. Onoe Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb J. Immunol. 164 2000 1230 1235
61. A. Saha, and S.K. Chatterjee Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer Scand. J. Immunol. 71 2010 70 82
62. A.E. Pedersen, S. Buus, and M.H. Claesson Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4 Cancer Lett. 235 2006 229 238
63. O. Met, M. Wang, A.E. Pedersen, M.H. Nissen, S. Buus, and M.H. Claesson The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling Cancer Lett. 231 2006 247 256
64. M. Muccioli, and F. Benencia Toll-like receptors in ovarian cancer as targets for immunotherapies Front. Immunol. 5 2014 341
65. B.J. Monk, W.E. Brady, H.A. Lankes, A. Facciabene, K. Manjarrez, R.M. Hershberg, and et al. VTX-2337, a TLR8 agonist, plus chemotherapy in recurrent ovarian cancer: preclinical and phase I data by the Gynecologic Oncology Group J. Clin. Oncol. 31 2013 (Suppl.; abstr 3077)
66. M.B. Fuertes, A.K. Kacha, J. Kline, S.R. Woo, D.M. Kranz, K.M. Murphy, and et al. Host type I IFN signals are required for antitumor CD8 + T cell responses through CD8{alpha} + dendritic cells J. Exp. Med. 208 2011 2005 2016
67. M.S. Diamond, M. Kinder, H. Matsushita, M. Mashayekhi, G.P. Dunn, J.M. Archambault, and et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors J. Exp. Med. 208 2011 1989 2003
68. G. Abdulhay, P.J. DiSaia, J.A. Blessing, and W.T. Creasman Human lymphoblastoid interferon in the treatment of advanced epithelial ovarian malignancies: a Gynecologic Oncology Group Study Am. J. Obstet. Gynecol. 152 1985 418 423
69. G.D. Hall, J.M. Brown, R.E. Coleman, M. Stead, K.S. Metcalf, K.R. Peel, and et al. Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study Br. J. Cancer 91 2004 621 626
70. D.S. Alberts, E.V. Hannigan, P.Y. Liu, C. Jiang, S. Wilczynski, L. Copeland, and et al. Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study Gynecol. Oncol. 100 2006 133 138
71. K.H. Kim, I.P. Dmitriev, S. Saddekni, E.A. Kashentseva, R.D. Harris, R. Aurigemma, and et al. A phase I clinical trial of Ad5/3-Delta24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer Gynecol. Oncol. 130 2013 518 524
72. K.H. Kim, I. Dmitriev, J.P. O'Malley, M. Wang, S. Saddekni, Z. You, and et al. A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer Clin. Cancer Res. 18 2012 3440 3451
73. K.J. Kimball, M.A. Preuss, M.N. Barnes, M. Wang, G.P. Siegal, W. Wan, and et al. A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases Clin. Cancer Res. 16 2010 5277 5287
74. E. Galanis, L.C. Hartmann, W.A. Cliby, H.J. Long, P.P. Peethambaram, B.A. Barrette, and et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer Cancer Res. 70 2010 875 882
75. J.K. Wolf, D.C. Bodurka, J.B. Gano, M. Deavers, L. Ramondetta, P.T. Ramirez, and et al. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer Gynecol. Oncol. 94 2004 442 448
76. P.A. Vasey, L.N. Shulman, S. Campos, J. Davis, M. Gore, S. Johnston, and et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer J. Clin. Oncol. 20 2002 1562 1569
77. A. Hemminki, M. Wang, R.A. Desmond, T.V. Strong, R.D. Alvarez, and D.T. Curiel Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy Hum. Gene Ther. 13 2002 1505 1514
78. A. Hasenburg, D.C. Fischer, X.W. Tong, A. Rojas-Martinez, C. Nyberg-Hoffman, M. Orlowska-Volk, and et al. Histologic and immunohistochemical analysis of tissue response to adenovirus-mediated herpes simplex thymidine kinase gene therapy of ovarian cancer Int. J. Gynecol. Cancer 12 2002 66 73
79. R.E. Buller, I.B. Runnebaum, B.Y. Karlan, J.A. Horowitz, M. Shahin, T. Buekers, and et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer Cancer Gene Ther. 9 2002 553 566
80. A. Hasenburg, X.W. Tong, D.C. Fischer, A. Rojas-Martinez, C. Nyberg-Hoffman, A.L. Kaplan, and et al. Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up Gynecol. Oncol. 83 2001 549 554
81. R.D. Alvarez, J. Gomez-Navarro, M. Wang, M.N. Barnes, T.V. Strong, R.B. Arani, and et al. Adenoviral-mediated suicide gene therapy for ovarian cancer Mol. Ther. 2 2000 524 530
82. R.D. Alvarez, M.N. Barnes, J. Gomez-Navarro, M. Wang, T.V. Strong, W. Arafat, and et al. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial Clin. Cancer Res. 6 2000 3081 3087
83. G.A. Fyfe, R.I. Fisher, S.A. Rosenberg, M. Sznol, D.R. Parkinson, and A.C. Louie Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy J. Clin. Oncol. 14 1996 2410 2411
84. E. Chang, and S.A. Rosenberg Patients with melanoma metastases at cutaneous and subcutaneous sites are highly susceptible to interleukin-2-based therapy J. Immunother. 24 2001 88 90
85. S.F. Wolf, P.A. Temple, M. Kobayashi, D. Young, M. Dicig, L. Lowe, and et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells J. Immunol. 146 1991 3074 3081
86. G. Trinchieri Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes Blood 84 1994 4008 4027
87. R.P. Edwards, W. Gooding, B.C. Lembersky, K. Colonello, R. Hammond, C. Paradise, and et al. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion J. Clin. Oncol. 15 1997 3399 3407
88. D.M. Mahvi, M.B. Henry, M.R. Albertini, S. Weber, K. Meredith, H. Schalch, and et al. Intratumoral injection of IL-12 plasmid DNA-results of a phase I/IB clinical trial Cancer Gene Ther. 14 2007 717 723
89. A.I. Daud, R.C. DeConti, S. Andrews, P. Urbas, A.I. Riker, V.K. Sondak, and et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma J. Clin. Oncol. 26 2008 5896 5903
90. K. Anwer, F.J. Kelly, C. Chu, J.G. Fewell, D. Lewis, and R.D. Alvarez Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer Gynecol. Oncol. 131 2013 169 173
91. R.D. Alvarez, M.W. Sill, S.A. Davidson, C.Y. Muller, D.P. Bender, R.L. DeBernardo, and et al. A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study Gynecol. Oncol. 133 2014 433 438
92. D. Zamarin, and M.A. Postow Immune checkpoint modulation: rational design of combination strategies Pharmacol. Ther. 150 2015 23 32
93. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, J.B. Haanen, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N. Engl. J. Med. 363 2010 711 723
94. O. Hamid, C. Robert, A. Daud, F.S. Hodi, W.J. Hwu, R. Kefford, and et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N. Engl. J. Med. 369 2013 134 144
95. J. Hamanishi, M. Mandai, T. Ikeda, M. Minami, A. Kawaguchi, T. Murayama, and et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer J. Clin. Oncol. 2015
96. F.S. Hodi, M. Butler, D.A. Oble, M.V. Seiden, F.G. Haluska, A. Kruse, and et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients Proc. Natl. Acad. Sci. U. S. A. 105 2008 3005 3010
97. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, W.J. Hwu, S.L. Topalian, P. Hwu, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N. Engl. J. Med. 366 2012 2455 2465
98. M.L. Disis, M.R. Patel, S. Pant, J.R. Infante, A.C. Lockhart, K. Kelly, and et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial J. Clin. Oncol. 33 2015 (Suppl.; abstr 5509)
99. A. Varga, S.A. Piha-Paul, P.A. Ott, J.M. Mehnert, D. Berton-Rigaud, E.A. Johnson, J.D. Cheng, S. Yuan, E.H. Rubin, and D.E. Matei Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study J. Clin. Oncol. 33 2015 (Suppl.; abstr 5510)
100. M.A. Curran, W. Montalvo, H. Yagita, and J.P. Allison PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors Proc. Natl. Acad. Sci. U. S. A. 107 2010 4275 4280
101. J. Duraiswamy, K.M. Kaluza, G.J. Freeman, and G. Coukos Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors Cancer Res. 73 2013 3591 3603
102. J.D. Wolchok, H. Kluger, M.K. Callahan, M.A. Postow, N.A. Rizvi, and A.M. Lesokhin Nivolumab plus ipilimumab in advanced melanoma N. Engl. J. Med. 369 2013 122 133
103. H.J. Hammers, E.R. Plimack, J.R. Infante, M.S. Ernstoff, B.I. Rini, D.F. McDermott, and et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC) J. Clin. Oncol. 32 2014 (Suppl.; abstr 4504)
104. J. Larkin, V. Chiarion-Sileni, R. Gonzalez, G. JJ, C. CL, L. CD, and et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N. Engl. J. Med. 2015
105. S.A. Rosenberg, B.S. Packard, P.M. Aebersold, D. Solomon, S.L. Topalian, S.T. Toy, and et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report N. Engl. J. Med. 319 1988 1676 1680
106. K. Fujita, H. Ikarashi, K. Takakuwa, S. Kodama, A. Tokunaga, T. Takahashi, and et al. Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes Clin. Cancer Res. 1 1995 501 507
107. Y. Aoki, K. Takakuwa, S. Kodama, K. Tanaka, M. Takahashi, A. Tokunaga, and et al. Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer Cancer Res. 51 1991 1934 1939
108. E.L. Smith, D. Zamarin, and A.M. Lesokhin Harnessing the immune system for cancer therapy Curr. Opin. Oncol. 26 2014 600 607
109. M. Koneru, T.J. Purdon, D. Spriggs, S. Koneru, and R.J. Brentjens IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors Oncoimmunology 4 2015 e994446
110. A.A. Chekmasova, T.D. Rao, Y. Nikhamin, K.J. Park, D.A. Levine, D.R. Spriggs, and et al. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen Clin. Cancer Res. 16 2010 3594 3606
111. M. Koneru, R. O'Cearbhaill, S. Pendharkar, D.R. Spriggs, and R.J. Brentjens A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer J. Transl. Med. 13 2015 102
112. L.E. Kandalaft, D.J. Powell Jr., and G. Coukos A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer J. Transl. Med. 10 2012 157
113. M.L. Davila, I. Riviere, X. Wang, S. Bartido, J. Park, K. Curran, and et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia Sci. Transl. Med. 6 2014 224ra25
114. S.A. Grupp, M. Kalos, D. Barrett, R. Aplenc, D.L. Porter, S.R. Rheingold, and et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia N. Engl. J. Med. 368 2013 1509 1518
115. R.A. Morgan, J.C. Yang, M. Kitano, M.E. Dudley, C.M. Laurencot, and S.A. Rosenberg Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 Mol. Ther. 18 2010 843 851
116. E.Y. Woo, C.S. Chu, T.J. Goletz, K. Schlienger, H. Yeh, G. Coukos, and et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer Cancer Res. 61 2001 4766 4772
117. T.J. Curiel, G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, and et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat. Med. 10 2004 942 949
118. C. Lan, X. Huang, S. Lin, H. Huang, Q. Cai, T. Wan, and et al. Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer Technol. Cancer Res. Treat. 12 2013 259 267
119. S. Reinartz, T. Schumann, F. Finkernagel, A. Wortmann, J.M. Jansen, W. Meissner, and et al. Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse Int. J. Cancer 134 2014 32 42
120. I. Kryczek, S. Wei, G. Zhu, L. Myers, P. Mottram, P. Cheng, and et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma Cancer Res. 67 2007 8900 8905
121. J. Hamanishi, M. Mandai, M. Iwasaki, T. Okazaki, Y. Tanaka, K. Yamaguchi, and et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer Proc. Natl. Acad. Sci. U. S. A. 104 2007 3360 3365
122. X. Zang, P.S. Sullivan, R.A. Soslow, R. Waitz, V.E. Reuter, A. Wilton, and et al. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas Mod. Pathol. 23 2010 1104 1112
123. T. Inaba, K. Ino, H. Kajiyama, E. Yamamoto, K. Shibata, A. Nawa, and et al. Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma Gynecol. Oncol. 115 2009 185 192
124. R.P. Sutmuller, L.M. van Duivenvoorde, A. van Elsas, T.N. Schumacher, M.E. Wildenberg, J.P. Allison, and et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses J. Exp. Med. 194 2001 823 832
125. A.J. Rech, and R.H. Vonderheide Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells Ann. N. Y. Acad. Sci. 1174 2009 99 106
126. S. Telang, M.A. Rasku, A.L. Clem, K. Carter, A.C. Klarer, W.R. Badger, and et al. Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma BMC Cancer 11 2011 515
127. D. Sugiyama, H. Nishikawa, Y. Maeda, M. Nishioka, A. Tanemura, I. Katayama, and et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3 + CD4 + regulatory T cells, evoking antitumor immune responses in humans Proc. Natl. Acad. Sci. U. S. A. 110 2013 17945 17950
128. M. Ogura, T. Ishida, K. Hatake, M. Taniwaki, K. Ando, K. Tobinai, and et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma J. Clin. Oncol. 32 2014 1157 1163
129. Y. Zhu, B.L. Knolhoff, M.A. Meyer, T.M. Nywening, B.L. West, J. Luo, and et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T cell checkpoint immunotherapy in pancreatic cancer models Cancer Res. 2014
130. C.A. Gomez-Roca, P.A. Cassier, A. Italiano, M. Cannarile, C. Ries, C.M. Brillouet, and et al. Phase I study of RG7155, a novel anti-CSF1R antibody, in patients with advanced/metastatic solid tumors J. Clin. Oncol. 33 2015 (Suppl.; abstr 3005)
131. A. Vanderstraeten, S. Tuyaerts, and F. Amant The immune system in the normal endometrium and implications for endometrial cancer development J. Reprod. Immunol. 109 2015 7 16
132. A.D. Santin, P.L. Hermonat, A. Ravaggi, S. Bellone, C. Cowan, C. Coke, and et al. Development and therapeutic effect of adoptively transferred T cells primed by tumor lysate-pulsed autologous dendritic cells in a patient with metastatic endometrial cancer Gynecol. Obstet. Investig. 49 2000 194 203
133. A.D. Santin, S. Bellone, A. Ravaggi, J.J. Roman, S. Pecorelli, G.P. Parham, and et al. Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer Br. J. Cancer 86 2002 151 157
134. A. Coosemans, A. Vanderstraeten, S. Tuyaerts, T. Verschuere, P. Moerman, Z.N. Berneman, and et al. Wilms' Tumor Gene 1 (WT1)-loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial Anticancer Res. 33 2013 5495 5500
135. L.B. Alexandrov, S. Nik-Zainal, D.C. Wedge, S.A. Aparicio, S. Behjati, A.V. Biankin, and et al. Signatures of mutational processes in human cancer Nature 500 2013 415 421
136. B.E. Howitt, S.A. Shukla, L.M. Sholl, L.L. Ritterhouse, J.C. Watkins, S. Rodig, and et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1 JAMA Oncol. 2015
137. R. Dolcetti, A. Viel, C. Doglioni, A. Russo, M. Guidoboni, E. Capozzi, and et al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability Am. J. Pathol. 154 1999 1805 1813
138. N.J. Llosa, M. Cruise, A. Tam, E.C. Wicks, E.M. Hechenbleikner, J.M. Taube, and et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints Cancer Discov. 5 2015 43 51
139. D.T. Le, J.N. Uram, H. Wang, B.R. Bartlett, H. Kemberling, A.D. Eyring, and et al. PD-1 blockade in tumors with mismatch-repair deficiency N. Engl. J. Med. 372 2015 2509 2520
140. Cancer Genome Atlas Research N, K. C, S. N, C. AD, A. R, L. Y, and et al. Integrated genomic characterization of endometrial carcinoma Nature 497 2013 67 73
141. S. Bellone, F. Centritto, J. Black, C. Schwab, D. English, E. Cocco, and et al. Polymerase epsilon (POLE) ultra-mutated tumors induce robust tumor-specific CD4 + T cell responses in endometrial cancer patients Gynecol. Oncol. 138 2015 11 17
142. C.C. Billingsley, D.E. Cohn, D.G. Mutch, J.A. Stephens, A.A. Suarez, and P.J. Goodfellow Polymerase varepsilon (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing Cancer 121 2015 386 394
143. S. Bakhsh, M. Kinloch, L.N. Hoang, R. Soslow, M. Kobel, C.H. Lee, and et al. Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy Histopathology 2015
144. E. Cocco, Z. Hu, C.E. Richter, S. Bellone, F. Casagrande, M. Bellone, and et al. hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma Br. J. Cancer 103 2010 812 819
145. J. Varughese, E. Cocco, S. Bellone, M. de Leon, M. Bellone, P. Todeschini, and et al. Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody Cancer 117 2011 3163 3172
146. A. Vanderstraeten, T. Everaert, R. Van Bree, G. Verbist, C. Luyten, F. Amant, and et al. In vitro validation of survivin as target tumor-associated antigen for immunotherapy in uterine cancer J. Immunother. 38 2015 239 249
147. C.L. Satterwhite, E. Torrone, E. Meites, E.F. Dunne, R. Mahajan, M.C. Ocfemia, and et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008 Sex. Transm. Dis. 40 2013 187 193
148. G.M. Clifford, J.S. Smith, M. Plummer, N. Munoz, and S. Franceschi Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis Br. J. Cancer 88 2003 63 73
149. N. Kash, M.A. Lee, R. Kollipara, C. Downing, J. Guidry, and S.K. Tyring Safety and efficacy data on vaccines and immunization to human papillomavirus J. Clin. Med. 4 2015 614 633
150. J.M. Brotherton, and G.S. Ogilvie Current status of human papillomavirus vaccination Curr. Opin. Oncol. 27 2015 399 404
151. Z.H. H. Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypes Semin. Cancer Biol. 9 1999 405 411
152. S.J. McKee, A.S. Bergot, and G.R. Leggatt Recent progress in vaccination against human papillomavirus-mediated cervical cancer Rev. Med. Virol. 25 Suppl. 1 2015 54 71
153. B. Ma, B. Maraj, N.P. Tran, J. Knoff, A. Chen, R.D. Alvarez, and et al. Emerging human papillomavirus vaccines Expert Opin. Emerg. Drugs 17 2012 469 492
154. C. Remy-Ziller, C. Germain, A. Spindler, C. Hoffmann, N. Silvestre, R. Rooke, and et al. Immunological characterization of a modified vaccinia virus Ankara vector expressing the human papillomavirus 16 E1 protein Clin. Vaccine Immunol. 21 2014 147 155
155. R. Rosales, M. Lopez-Contreras, C. Rosales, J.R. Magallanes-Molina, R. Gonzalez-Vergara, J.M. Arroyo-Cazarez, and et al. Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine Hum. Gene Ther. 25 2014 1035 1049
156. L.K. Borysiewicz, A. Fiander, M. Nimako, S. Man, G.W. Wilkinson, D. Westmoreland, and et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer Lancet 347 1996 1523 1527
157. A. Wallecha, C. French, R. Petit, R. Singh, A. Amin, and J. Rothman Lm-LLO-based immunotherapies and HPV-associated disease J. Oncol. 2012 2012 542851
158. L. Cory, and C. Chu ADXS-HPV: a therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen Hum. Vaccin. Immunother. 10 2014 3190 3195
159. P.J. de Vos van Steenwijk, T.H. Ramwadhdoebe, M.J. Lowik, C.E. van der Minne, B.-v.d.M. DM, F. LM, and et al. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions Cancer Immunol. Immunother. 61 2012 1485 1492
160. K. Kawano, N. Tsuda, K. Waki, S. Matsueda, Y. Hata, K. Ushijima, and et al. Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy Cancer Sci. 106 2015 1111 1117
161. L.D. Roman, S. Wilczynski, L.I. Muderspach, A.F. Burnett, A. O'Meara, J.A. Brinkman, and et al. A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia Gynecol. Oncol. 106 2007 558 566
162. M.H. Einstein, A.S. Kadish, R.D. Burk, M.Y. Kim, S. Wadler, H. Streicher, and et al. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III Gynecol. Oncol. 106 2007 453 460
163. G.G. Kenter, M.J. Welters, A.R. Valentijn, M.J. Lowik, B.-v.d.M. DM, V. AP, and et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia N. Engl. J. Med. 361 2009 1838 1847
164. C.L. Trimble, S. Peng, F. Kos, P. Gravitt, R. Viscidi, E. Sugar, and et al. A phase I trial of a human papillomavirus DNA vaccine for HPV16 + cervical intraepithelial neoplasia 2/3 Clin. Cancer Res. 15 2009 361 367
165. N. Bloy, A. Buque, F. Aranda, F. Castoldi, A. Eggermont, I. Cremer, and et al. Trial watch: naked and vectored DNA-based anticancer vaccines Oncoimmunology 4 2015 e1026531
166. A.D. Santin, S. Bellone, M. Gokden, M.J. Cannon, and G.P. Parham Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer N. Engl. J. Med. 346 2002 1752 1753
167. A.D. Santin, S. Bellone, M. Palmieri, A. Zanolini, A. Ravaggi, E.R. Siegel, and et al. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial J. Virol. 82 2008 1968 1979
168. L. Muderspach, S. Wilczynski, L. Roman, L. Bade, J. Felix, L.A. Small, and et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive Clin. Cancer Res. 6 2000 3406 3416
169. A.D. Santin, S. Bellone, M. Palmieri, A. Ravaggi, C. Romani, R. Tassi, and et al. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities Gynecol. Oncol. 100 2006 469 478
170. L. Mezache, B. Paniccia, A. Nyinawabera, and G.J. Nuovo Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers Mod. Pathol. 2015
171. A.M. Heeren, B.D. Koster, S. Samuels, D.M. Ferns, D. Chondronasiou, G.G. Kenter, and et al. High and interrelated rates of PD-L1 + CD14 + antigen-presenting cells and regulatory T cells mark the microenvironment of metastatic lymph nodes from patients with cervical cancer Cancer Immunol. Res. 3 2015 48 58
172. S. Lyford-Pike, S. Peng, G.D. Young, J.M. Taube, W.H. Westra, B. Akpeng, and et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma Cancer Res. 73 2013 1733 1741
173. S. Stevanovic, L.M. Draper, M.M. Langhan, T.E. Campbell, M.L. Kwong, J.R. Wunderlich, and et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells J. Clin. Oncol. 33 2015 1543 1550
174. C.A. Ramos, N. Narala, G.M. Vyas, A.M. Leen, U. Gerdemann, E.M. Sturgis, and et al. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies J. Immunother. 36 2013 66 76